All In Biotech

NDA 202270 · Msd Sub Merck

Janumet Xr

Metformin Hydrochloride, Sitagliptin Phosphate · Oral

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 2, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,828

753 Phase 3, 150 recruiting

FAERS reports

21,623

14,062 serious, 2,125 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...

What it is approved for

From the label in effect Aug 11, 2026.

JANUMET ® XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUMET XR is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not for the treatment of type 1 diabetes. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 , 5.2 ) Limitations of Use JANUMET XR should not be used in patients with type 1 diabetes mellitus. JANUMET XR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET XR [see Warnings and Precautions (5.2) ].

Mechanism: JANUMET XR JANUMET XR tablets combine two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in adults with type 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin extended-release, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which exerts its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • JANUMET XR · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • JANUMET XR · METFORMIN HYDROCHLORIDE 500MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • JANUMET XR · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.

All 2,828 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,511
  • diarrhoea1,398
  • nausea1,110
  • drug ineffective1,006
  • fatigue902
  • acute kidney injury838
  • vomiting781
  • weight decreased718
  • dizziness639
  • pancreatitis626
  • dyspnoea623
  • no adverse event623

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200739
2008131
2009254
2010384
2011539
2012929
20131,368
20141,814
20152,375
20162,094
20171,659
20181,792
20191,645
20201,564
20211,323
20221,058
2023926
2024752
2025598
2026379

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Janumet XR (Sitagliptin Phos/Metformin HCl)

2024 spending

$358M

Beneficiaries

85,930

382,969 claims

Per beneficiary

$4,166

$12.17 per unit

View as table
YearSpending
2020$366,629,236
2021$389,364,879
2022$397,328,690
2023$392,139,531
2024$357,969,900

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,495 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.